KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Non-Current Liabilities (2016 - 2025)

Gsk (GSK) has 8 years of Total Non-Current Liabilities data on record, last reported at $31.7 billion in Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities rose 1.51% year-over-year to $31.7 billion; the TTM value through Dec 2024 reached $31.7 billion, up 1.51%, while the annual FY2024 figure was $31.5 billion, 0.88% up from the prior year.
  • Total Non-Current Liabilities reached $31.7 billion in Q4 2024 per GSK's latest filing, up from $31.2 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $46.0 billion in Q4 2021 and bottomed at $31.2 billion in Q4 2023.
  • Average Total Non-Current Liabilities over 4 years is $35.2 billion, with a median of $31.8 billion recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 30.47% in 2022, then increased 1.51% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $46.0 billion in 2021, then crashed by 30.47% to $32.0 billion in 2022, then dropped by 2.33% to $31.2 billion in 2023, then increased by 1.51% to $31.7 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $31.7 billion in Q4 2024, $31.2 billion in Q4 2023, and $32.0 billion in Q4 2022.